212Pb-satoreotide

212Pb-satoreotide is a radiopharmaceutical drug consisting of the somatostatin receptor 2 (SSTR2) antagonist satoreotide labeled with the alpha-emitting radioisotope lead-212 (^212Pb). It is designed for targeted alpha therapy of cancers that overexpress SSTR2, such as small cell lung cancer (SCLC) and neuroendocrine tumors. Satoreotide binds to SSTR2 on tumor cells, delivering localized radiation from ^212Pb to induce DNA damage and cell death. Preclinical studies have shown that while ^225Ac-labeled satoreotide demonstrated superior efficacy compared to agonist-based agents, ^212Pb-labeled satoreotide had lower tumor uptake and was not more potent than lutetium or terbium analogs; it also caused more side effects in preclinical models, leading developers not to pursue further clinical development of this isotope conjugate[1][2]. The drug was developed by Ariceum Therapeutics.

Other names

SSO110 (when labeled with other isotopes)satoreotide (parent molecule)